Prostate cancer patients who do not respond well to PSMA-targeted therapy often have potentially treatable mutations in their DNA damage-repair genes, according to research published in the May issue of The Journal of Nuclear ...
May 21, 2020
0
3
The same genes that greatly increase the risk of breast cancer in U.S. white women, including women of Ashkenazi Jewish descent, also greatly increase breast cancer risk among African American women. These genes include the ...
May 19, 2020
0
66
Assessing adverse childhood experiences and current anxiety and depression symptoms may help ease cognitive distress in women who have undergone a surgical menopause for cancer risk-reduction, or RRSO, according to a new ...
Mar 26, 2020
0
1
Nearly one-third of women who choose to have their ovaries removed before the natural age of menopause are susceptible to negative mood and executive dysfunction. A new study shows that a woman's risk for such disorders may ...
Mar 18, 2020
0
1
About 1 in 40 postmenopausal women diagnosed with breast cancer before age 65 have cancer-associated mutations in their BRCA1 or BRCA2 genes, according to a Stanford-led study of more than 4,500 participants in the long-running ...
Mar 10, 2020
0
5
Women with early stage breast cancer who test positive for an inherited genetic variant are not always receiving cancer treatment that follows current guidelines, a new study finds.
Feb 6, 2020
0
5
A new study has uncovered a previously unknown role for the enzyme EXD2, identifying it as a potential drug target for cancer therapy.
Dec 19, 2019
0
2
Health reports from direct-to-consumer (DTC) genetic tests that use a limited variant screening approach often yield clinical false-negative results, which pose the risk of informing health care decisions based on incomplete ...
Oct 17, 2019
0
3
(HealthDay)—Unselected, multigene testing for all patients with breast cancer would be cost-effective in the United Kingdom and the United States, according to a study published online Oct. 3 in JAMA Oncology.
Oct 10, 2019
0
2
Targeting faulty DNA repair mechanisms in advanced castration resistant prostate cancer can slow progression and potentially improve survival, paving the way for a new approach to treatment of the most common form of cancer ...
Sep 30, 2019
0
4
